Document is current
Any future updates will be listed below
-
Authors
Culliford, Richard https://orcid.org/0000-0003-4534-9241
Lawrence, Samuel E. D.
Mills, Charlie https://orcid.org/0000-0002-4755-7549
Tippu, Zayd
Chubb, Daniel
Cornish, Alex J. https://orcid.org/0000-0002-3966-3501
Browning, Lisa
Kinnersley, Ben https://orcid.org/0000-0003-1783-6296
Bentham, Robert
Sud, Amit https://orcid.org/0000-0002-6133-0164
Pallikonda, Husayn https://orcid.org/0000-0003-4472-2067
,
Afshar, Mehran
Akala, Oyeyemi
Brown, Janet
Faust, Guy
Fife, Kate
Foy, Victoria
Germanou, Styliani
Giles, Megan
Grieco, Charlotte
Grummet, Simon
Jain, Ankit
Kanwar, Anuradha
Protheroe, Andrew
Raza, Iwan
Rehan, Ahmed
Rudman, Sarah
Santiapillai, Joseph
Sarwar, Naveed
Seeva, Pavetha
Strong, Amy
Toki, Maria
Tran, Maxine
Tutika, Rippie
Waddell, Tom
Wheater, Matthew
Frangou, Anna https://orcid.org/0000-0001-6990-2756
Gruber, Andreas J. https://orcid.org/0000-0001-7664-4257
Litchfield, Kevin https://orcid.org/0000-0002-3725-0914
Wedge, David https://orcid.org/0000-0002-7572-3196
Larkin, James
Turajlic, Samra https://orcid.org/0000-0001-8846-136X
Houlston, Richard S. https://orcid.org/0000-0002-5268-0242
- License Information
-
More Information
Article History
Received: 28 November 2023
Accepted: 17 June 2024
First Online: 15 July 2024
Competing interests
: S.T. has received speaking fees from Roche, AstraZeneca, Novartis and Ipsen. S.T. has the following patents filed: Indel mutations as a therapeutic target and predictive biomarker PCTGB2018/051892 and PCTGB2018/051893 and Clear Cell Renal Cell Carcinoma Biomarkers P113326GB. None of the other authors have a financial or non-financial conflict of interest.
